CEO, Damien McDevitt, Named in San Diego Business Journal’s 500 Most Influential People in San Diego

Our CEO, Damien McDevitt, was named in the San Diego Business Journal’s 500 Most Influential People in San Diego. With over two decades of experience in life sciences, Damien is leading our mission to bring personalized, induced pluripotent stem cell treatments to patients with Parkinson’s Disease.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.